Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00500318
Status:
COMPLETED
Last Update Posted:
2017-01-06
First Post:
2007-07-10
Brief Title:
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease COPD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide LAS34273 200 ug on Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD It was 9 weeks in duration consisting of a 2-week run-in period 6 weeks of double-blind treatment and a 1-week follow-up phone call All patients meeting the eligibility criteria were randomized to one of two treatment groups aclidinium bromide or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None